INTERPHEX 2023: STERILINE PROVIDES FLEXIBLE ROBOTIC TECHNOLOGIES
FOR SMALL BATCH ASEPTIC FILLING

Robotic applications for the primary packaging of Cell and Gene Therapies
to answer all customers’ needs

New York – 15th March 2023 – Steriline, a company highly specialised in filling solutions for the aseptic processing of injectable products, will present a new Robotic Nest Filling Machine at Interphex 2023 (Booth 2537), from 25th to 27th April in New York.

Steriline's robotic systems provide a high level of efficiency, safety and flexibility for the production of toxic and non-toxic drugs, reducing the risk of human error and improving overall quality. The company's technologies are specifically designed to meet the needs of key pharmaceutical sectors, such as the cell and gene therapy market, where quick turnaround of high-value product is critical.

Steriline's fully isolator-based robotic systems have a small footprint and are equipped with advanced technologies, including fully disposable fill paths, 100% in-process check-weighing combined with a “zero-loss philosophy”.

Steriline's solutions are designed according to the needs expressed by customers and are compatible with various primary containers such as vials, ampoules, cartridges, syringes and bags. The systems can handle products in both liquid and powder form and can be equipped with Laminar Air Flow (LAF), Open and Closed Restricted Access Barriers (oRABs, cRABs) and Isolator Barrier Systems (ISOs) to ensure air monitoring and compliance with FDA regulations and current Good Manufacturing Practices (cGMPs).

"Steriline introduced robotic applications into the aseptic processing market in 2014, one of the first players," said Federico Fumagalli, Chief Commercial Officer at Steriline. "Since then, we have been continuously adapting our technologies to address all the fill/finish operation needs of the pharma industry, including Cell & Gene Therapies, where the demand for quick turnaround of high-value product is critical."

James Rorke, Vice President North American Operations at Steriline, added: "When a batch is only a few litres of product and worth tens of thousands of dollars or more, our customers expect the highest yield from their fill/finish systems. Showing that we can deliver practically every drop of product into a vial or syringe, without product losses, and having the data to prove every single container has been filled to the optimal volume has been a game-changer for our customers."

ABOUT STERILINE
Steriline is a well-established European manufacturer, highly specialised in the production of complete lines for the aseptic processing of injectable products, supplying pharmaceutical companies worldwide.

Steriline was founded in 1989 in the Lake Como area (Italy), where its headquarters and manufacturing facilities are still based. With operations in over 50 countries around the world, Steriline has a network of over 220 people, including direct employees and external partners, in addition to 40 local sales representatives. Exports represent more than 90% of Steriline’s turnover, with over 1,800 machines installed throughout Asia, Europe, and the U.S.A.

Steriline develops, manufactures, and supplies a comprehensive range of solutions, including both mechanical and robotic applications for aseptic processing. These applications are consistent with vials, ampoules, cartridges and syringes and can handle toxic or non-toxic products in both liquid and powder form. Steriline’s complete lines include equipment ranging from washing machines, depyrogenation tunnels, filling and capping machines, to external decontamination machines and barrier systems such as LAF, oRABS, cRABS and isolators. For more information about Steriline: www.steriline.it.